The reverse transcriptase–polymerase chain reaction (RT-PCR) has become widely used for monitoring minimal residual disease after allogeneic stem cell transplantation (SCT) for chronic myeloid leukemia (CML). However, most of these studies were performed using qualitative RT-PCR, and the interpretation of the results obtained has been conflicting. The correlation of a quantitative RT-PCR test performed early after SCT (at 3 to 5 months) and long-term outcome of CML patients surviving for more than 6 months was studied. Between January 1991 and June 1999, data from 138 CML patients who received allografts were evaluated. Early RT-PCR results were classified as (1) negative if there were no BCR-ABLtranscripts detected (n = 61), (2) positive at low level if the total number of BCR-ABL transcripts was less than 100 per μg RNA and/or the BCR-ABL/ABL ratio was less than 0.02% (n = 14), or (3) positive at high level if transcript levels exceeded the thresholds defined above (n = 63). Three years after SCT the cumulative incidence of relapse was 16.7%, 42.9%, and 86.4%, respectively (P = .0001). The relationship betweenBCR-ABL transcript level and probability of relapse was apparent whether patients had received sibling or unrelated donor SCT and also whether or not the transplantation was T cell depleted. The results suggest that quantitative RT-PCR performed early after SCT is useful for predicting outcome and may help to define the need for further treatment.

At present, allogeneic stem cell transplantation (SCT) is the only curative treatment for patients with chronic myeloid leukemia (CML). Although allogeneic SCT often results in the disappearance of the Ph chromosome, this Ph negativity does not exclude the presence of residual leukemic cells because the sensitivity of cytogenetic analysis is low. The chimeric BCR-ABL gene is a tumor-specific marker that allows detection of minimal residual disease (MRD) using a reverse transcriptase–polymerase chain reaction (RT-PCR) assay.1-4 

Several studies have attempted to assess the clinical significance and predictive value of detecting BCR-ABL transcripts by RT-PCR assay after SCT. However, most studies were performed using qualitative RT-PCR, and the results have been conflicting.1-8Moreover, the sensitivity of the RT-PCR assay varies considerably in different laboratories, and it is difficult to compare and interpret results reported by different investigators in the absence of internal quantitative controls. When the sensitivity of the assay is increased, only a few patients remain RT-PCR early after SCT, thus rendering RT-PCR “too sensitive” to serve a prognostic purpose.9 10 

Because nonquantitative RT-PCR analysis gives only limited information, several groups have developed quantitative or semiquantitative RT-PCR assays that enable the kinetics of residual disease to be monitored over time.11-15 If a threshold of residual disease can be established above which a patient is likely to relapse, then monitoring residual disease using quantitative RT-PCR would have clinical value. We have previously shown that in patients treated with interferon, low levels or absence of MRD is associated with continuing remission.16,17 After allogeneic SCT, serial quantitative RT-PCR analysis of peripheral blood specimens can effectively distinguish those patients who will remain in remission from those patients who are destined to relapse.11 13 Moreover, early recognition of relapse at the molecular level provides a window for therapeutic intervention while the burden of disease is still relatively low. In this study we have tested the value of a quantitative RT-PCR assay in predicting relapse when performed early (at 3 to 5 months) after SCT.

Patients

Between January 1991 and June 1999 a total of 238 consecutive patients with Ph+ chromosome and/orBCR-ABL+ CML in chronic phase (CP) or accelerated phase (AP) underwent allogeneic SCT at the Hammersmith Hospital in London, England, and survived for more than 6 months after SCT. All patients gave informed consent according to the Declaration of Helsinki. The study was approved by the Hammersmith Hospital research ethics committee. Data from early RT-PCR, performed within 3-5 months after SCT, were available for 138 of these patients. Characteristics of these patients are summarized in Table 1. The overall median age was 34.0 years (range, 6.5-56.7 years); the median interval from diagnosis to SCT was 14 months (range, 3-73 months). Of those patients who underwent an SCT, 67 patients received cells from a human leukocyte antigen (HLA)–identical sibling (SIB), and 71 patients received cells from an unrelated donor (URD). Where the donor was unrelated, iso-electric focusing and molecular typing for DRB1 were employed to confirm HLA identity at class I and II loci, respectively. Where a choice of unrelated donor existed, the cytotoxic T-lymphocyte precursor (CTLp) assay was used to aid donor selection.18 

Table 1.

Clinical characteristics of 138 chronic myeloid leukemia patients according to early reverse transcriptase–polymerase chain reaction results after allogeneic stem cell transplantation

NegativeLow-level positiveHigh-level positiveP
Sex, no. (%)     
 Male 30 (49) 6 (43) 38 (60) NS 
 Female 31 (51) 8 (57) 25 (40)  
Age, y*(range) 33.5 35.5 33.9 NS 
 (6.5-55.4) (22.6-54.2) (9.7-56.7)  
Type of donor, no. (%)     
 SIB 36 (59) 7 (50) 24 (38) .01 
 URD 25 (41) 7 (50) 39 (62)  
Interval from diagnosis to SCT,  mo*(range) 11 (4-73) 15 (4-36) 15 (3-64) NS 
Disease status at SCT, no. (%)     
 Chronic phase 51 (84) 10 (71) 52 (83) NS 
 Accelerated phase 10 (16) 4 (29) 11 (17)  
GVHD prophylaxis, no. (%)     
 Non-TCD 33 (54) 6 (43) 20 (32) .02 
 TCD 28 (46) 8 (57) 43 (68)  
CMV seropositive, no. (%) 26 (43) 8 (57) 27 (42) NS  
Acute GVHD after SCT, no. (%)     
 0-I 23 (38) 7 (50) 33 (52)  
 II 32 (52) 5 (36) 27 (43) NS 
 III-IV 6 (10) 2 (14) 3 (5)  
NegativeLow-level positiveHigh-level positiveP
Sex, no. (%)     
 Male 30 (49) 6 (43) 38 (60) NS 
 Female 31 (51) 8 (57) 25 (40)  
Age, y*(range) 33.5 35.5 33.9 NS 
 (6.5-55.4) (22.6-54.2) (9.7-56.7)  
Type of donor, no. (%)     
 SIB 36 (59) 7 (50) 24 (38) .01 
 URD 25 (41) 7 (50) 39 (62)  
Interval from diagnosis to SCT,  mo*(range) 11 (4-73) 15 (4-36) 15 (3-64) NS 
Disease status at SCT, no. (%)     
 Chronic phase 51 (84) 10 (71) 52 (83) NS 
 Accelerated phase 10 (16) 4 (29) 11 (17)  
GVHD prophylaxis, no. (%)     
 Non-TCD 33 (54) 6 (43) 20 (32) .02 
 TCD 28 (46) 8 (57) 43 (68)  
CMV seropositive, no. (%) 26 (43) 8 (57) 27 (42) NS  
Acute GVHD after SCT, no. (%)     
 0-I 23 (38) 7 (50) 33 (52)  
 II 32 (52) 5 (36) 27 (43) NS 
 III-IV 6 (10) 2 (14) 3 (5)  

NS indicates not sufficient data; SIB, sibling donor; URD, unrelated donor; SCT, stem cell transplantation; GVHD, graft-versus-host disease; TCD, T-cell depletion; CMV, cytomegalovirus.

*

Median values.

The transplantation conditioning and prophylaxis against graft-versus-host disease (GVHD) were performed according to our standard protocols as previously described.18 19 All patients were conditioned with 120 mg/kg cyclophosphamide and 1200-1440 cGy total body irradiation in 6 fractions for 3 days. In addition, some patients received busulfan, daunorubicin, cytarabine, thiotepa, and/or splenic irradiation. Patients receiving stem cells from an unrelated donor were given intravenous anti-CD52 monoclonal antibody (mAb) (Campath 1G or 1H; Therapeutic Antibody Center–TAC, Oxford, United Kingdom) from day −5 to day +4 as a method of T-cell depletion (TCD). In addition, Campath was used in vitro to treat the bone marrow of 8 SIB donors. All patients received cyclosporine and “short” methotrexate as GVHD prophylaxis. Four patients received 10 mg/kg antithymocyte globulin (ATG) instead of Campath antibody in 1992 because Campath was temporarily unavailable.

Molecular monitoring

Peripheral blood samples in all cases were studied every 3 months after SCT for the presence of BCR-ABL transcripts using a double-step, nested, semiquantitative RT-PCR assay as previously described.3,11 Bone marrow samples for cytogenetic analysis were performed when clinically indicated. The frequency of cytogenetic and RT-PCR monitoring after transplantation was similar in the SIB and URD transplantations. If a sample was found positive by RT-PCR testing, quantitation was performed by competitive RT-PCR, and further samples were analyzed at monthly intervals. Until 1996 results were expressed as the number of BCR-ABLtranscripts per μg RNA. Subsequently, results were expressed as theBCR-ABL/ABL ratio, the number of total ABLtranscripts (including BCR-ABL) serving as an internal control for sample quality.11 13 

Classification of “early” RT-PCR results

Early RT-PCR was defined as a quantitative RT-PCR performed between 3 and 5 months after SCT. For patients with more than one sample analyzed, the highest level of RT-PCR positivity was considered. In a previous study we showed that for patients who in sequential sampling remained below a ratio of 0.02%, the probability of relapse was extremely low.13 Therefore we have used the 0.02% cutoff for classifying early RT-PCR samples. The results of early RT-PCR were classified as (1) negative if there were noBCR-ABL transcripts detected; (2) low-level positive if the total number of BCR-ABL transcripts was less than 100 per μg RNA and/or the BCR-ABL/ABL ratio was less than 0.02%; or (3) high-level positive if transcript levels exceeded the thresholds defined above.

Definition of relapse

Currently we classify a patient as having molecular relapse if (1) the BCR-ABL/ABL ratio is more than 0.02% on 3 consecutive occasions at least one month apart; (2) the ratio is more than 0.05% on 2 consecutive samples; or (3) the transcript number is rising in 3 consecutive samples, with the last 2 samples greater than 0.02%. This molecular relapse was dated from the time of the first detection of BCR-ABL positivity, including the results of the early RT-PCR. Cytogenetic relapse is considered to be present if one or more Ph+ metaphases were detected on 2 consecutive analyses without evidence of hematologic relapse. Hematologic relapse is defined as peripheral blood leukocytosis usually with the presence of myelocytes, basophils, and an excess of neutrophils in the differential count with a hypercellular bone marrow. A functional definition of disease recurrence after SCT was used in this study to calculate the incidence of relapse after SCT. This disease recurrence was defined by the detection of any type of relapse (molecular, cytogenetic, or hematologic) and the need for antileukemia therapy.1 

Statistical analysis

The Fisher exact test, χ2 test, or χ2 trend test, and the Mann-Whitney test were employed to compare groups where appropriate. Survival and leukemia-free probabilities were calculated by the Kaplan-Meier method.20 The probability of relapse was calculated by the cumulative incidence procedure.21 The “failure of interest” was molecular, cytogenetic, or hematologic relapse, whichever was recognized first, and death without relapse was the competing risk. The log-rank test was used to compare survival curves. All quoted P values are 2-sided, and confidence intervals (CI) refer to 95% boundaries.

Early RT-PCR

Of the 138 patients with early RT-PCR tests, 63 (46%) patients were classified as high-level positive, 14 (10%) patients were low-level positive, and 61 (44%) patients were negative. In the high-level positive group, 24 (38%) patients received SIB transplantations and 39 (62%) patients received URD transplantations. In the negative group, 36 (59%) patients received SIB transplantations, and 25 (41%) patients received URD transplantations. In the low-level positive group, the distribution was equally balanced; 7 patients received SIB transplantations, and 7 patients received URD transplantations. Clinical characteristics and transplantation-related factors were distributed homogeneously between all 3 groups, with the exception of a significantly greater proportion of patients undergoing TCD and URD SCT in the high-level positive cohort (Table 1).

Association of early RT-PCR positivity and subsequent relapse

Of the 63 patients who had high-level positive RT-PCR, 52 (83%) patients relapsed at the molecular, cytogenetic, or hematologic level, and 11 (17%) patients have remained in continuous remission, with a median follow-up of 16 months (range, 7-92 months) (Table2). In the low-level positive group, 8 (57%) of 14 patients relapsed. In contrast, of the 61 patients who had negative RT-PCR results, only 14 (23%) patients relapsed, and 47 (77%) patients remained in remission after a median follow-up of 36 months (range, 7-103 months). The cumulative incidence of relapse for patients with high-level positive RT-PCR was 86.4% at 3 years compared with 42.9% for patients with low-level positive RT-PCR and 16.7% for patients with negative RT-PCR results (P < .0001) (Figure1). A further analysis was performed in which relapse was defined only on cytogenetic or hematologic criteria, and patients whose disease did not progress beyond molecular relapse were classified as “nonrelapsed” patients (Figure2). In this analysis, the cumulative incidence of relapse at 3 years was 74% for the high-level positive group versus 30% for the low-level group and 9% for the negative group (P < .0001).

Table 2.

Association between incidence of relapse and early reverse transcriptase–polymerase chain reaction result

Patients relapsed, no.Patients in continuous remission, no.Total patients, no.
RT-PCR result    
 Negative 14 47 61  
 Low-level positive 14  
 High-level positive 52 11 63 
Total patients, no. 74 64 138 
Patients relapsed, no.Patients in continuous remission, no.Total patients, no.
RT-PCR result    
 Negative 14 47 61  
 Low-level positive 14  
 High-level positive 52 11 63 
Total patients, no. 74 64 138 

RT-PCR indicates reverse transcriptase–polymerase chain reaction.

Fig. 1.

Cumulative incidence of relapse after SCT for CML according to results of an early RT-PCR test.

Cumulative incidence of disease recurrence at any (molecular, cytogenetic, or hematologic) level for patients with negative, low-level positive, and high-level positive RT-PCR at 3-5 months after SCT, respectively. The P value shown has been pooled over strata. The pairwise over strata P values are negative versus low positive, P = .01; negative versus high positive, P < .0001; and low positive versus high positive, P = .001.

Fig. 1.

Cumulative incidence of relapse after SCT for CML according to results of an early RT-PCR test.

Cumulative incidence of disease recurrence at any (molecular, cytogenetic, or hematologic) level for patients with negative, low-level positive, and high-level positive RT-PCR at 3-5 months after SCT, respectively. The P value shown has been pooled over strata. The pairwise over strata P values are negative versus low positive, P = .01; negative versus high positive, P < .0001; and low positive versus high positive, P = .001.

Close modal
Fig. 2.

Cumulative incidence of relapse at the cytogenetic or hematologic level after SCT for CML according to results of an early RT-PCR test.

Relapse is defined only on cytogenetic or hematologic criteria, and patients whose disease did not progress beyond molecular relapse are classified as “nonrelapsed” patients. The P value shown has been pooled over strata. The pairwise over strata Pvalues are negative versus low positive, P = .01; negative versus high positive, P < .0001; and low positive versus high positive, P = .001.

Fig. 2.

Cumulative incidence of relapse at the cytogenetic or hematologic level after SCT for CML according to results of an early RT-PCR test.

Relapse is defined only on cytogenetic or hematologic criteria, and patients whose disease did not progress beyond molecular relapse are classified as “nonrelapsed” patients. The P value shown has been pooled over strata. The pairwise over strata Pvalues are negative versus low positive, P = .01; negative versus high positive, P < .0001; and low positive versus high positive, P = .001.

Close modal

When patients were subdivided by donor type, the cumulative incidence of relapse for the SIB and URD subgroups remained significantly higher for patients with a high-level positive result (Table3). In SIB recipients, patients with high-level positive RT-PCR had a cumulative incidence of relapse at 3 years of 70.6% compared with 28.6% in the low-level group and 10.5% in the negative group (P < .0001). In URD SCT, the cumulative incidence of relapse at 3 years in patients with high-level positive RT-PCR was 95% compared with 57% in the low-level group and 25% in the negative group (P < .0001).

Table 3.

Association between cumulative incidence of relapse at 3 years and early reverse transcriptase–polymerase chain reaction result according to different clinical variables

RT-PCR resultTotal patients, %Type of donor, %GVHD prophylaxis, %Disease stage, %
SIBURDTCDNon-TCDCPAP
Negative 16.7 10.5 25 26.4 6.2 14.8 28.7 
Low-level positive 42.9 28.6 57 62.5 16.7 50 3-150 
High-level positive 86.4 70.6 95 95.3 64.7 84.5 90.9 
RT-PCR resultTotal patients, %Type of donor, %GVHD prophylaxis, %Disease stage, %
SIBURDTCDNon-TCDCPAP
Negative 16.7 10.5 25 26.4 6.2 14.8 28.7 
Low-level positive 42.9 28.6 57 62.5 16.7 50 3-150 
High-level positive 86.4 70.6 95 95.3 64.7 84.5 90.9 

Cumulative incidence of relapse is expressed as probability (%) at 3 years after SCT.

CP indicates chronic phase; AP, accelerated phase; for other abbreviations, see Tables 1 and 2.

F3-150

Indicates less than 5 patients.

The probability of relapse remained significantly higher for patients with high-level positive RT-PCR when patients were subdivided according to GVHD prophylaxis (TCD versus non-TCD) and disease stage (CP vs AP) at SCT (Table 3). Patients who had received a TCD and URD SCT and had a high-level positive result in the early RT-PCR test showed a strong tendency to relapse rapidly after SCT. More than 89% of these patients relapsed within 9 months of SCT. Overall, for patients who have relapsed, the median time from SCT to relapse was 6 months (range, 3-92 months) for the high-level positive group compared with 19 months (range, 6-90 months) for the low-level positive group and 28 months (range, 6-99 months) for patients with a negative RT-PCR.

Management of relapse

Following SCT, 74 patients developed disease recurrence. Of these patients, 5 received no treatment or were treated with hydroxyurea, interferon-alpha, and/or other chemotherapy agents at the time of hematologic relapse (Table 4). The other 49 patients received donor lymphocyte infusion (DLI). The same proportion of patients received DLI in all 3 groups. The median time from first detection of relapse until DLI was identical in all 3 groups (10 months). Reasons for not having DLI included GVHD (5 patients), disease progression (5 patients), and withdrawal of immunosuppression (9 patients); in 9 cases, DLI had been planned but not yet implemented. At the time of DLI, 75% of patients in the negative RT-PCR group were in molecular or cytogenetic relapse compared with 43% and 35% in the low- and high-level groups, respectively.

Table 4.

Clinical evolution after relapse

RT-PCR result
Negative, no. (%)Low-level positive, no. (%)High-level positive, no. (%)
Treatment of relapse    
 DLI 8 (57) 7 (62) 34 (65) 
 Other 6 (43) 1 (38) 18 (35)  
Disease status at DLI    
 Molecular/cytogenetic 6 (75) 3 (43) 12 (35) 
 Hematologic 2 (25) 4 (57) 22 (65)  
Response to DLI    
 Molecular remission 4 (50) 5 (72) 14 (41)  
 No response 2 (25) 1 (14) 13 (38)  
 Not yet evaluable 2 (25) 1 (14) 7 (21) 
RT-PCR result
Negative, no. (%)Low-level positive, no. (%)High-level positive, no. (%)
Treatment of relapse    
 DLI 8 (57) 7 (62) 34 (65) 
 Other 6 (43) 1 (38) 18 (35)  
Disease status at DLI    
 Molecular/cytogenetic 6 (75) 3 (43) 12 (35) 
 Hematologic 2 (25) 4 (57) 22 (65)  
Response to DLI    
 Molecular remission 4 (50) 5 (72) 14 (41)  
 No response 2 (25) 1 (14) 13 (38)  
 Not yet evaluable 2 (25) 1 (14) 7 (21) 

RT-PCR indicates reverse transcriptase–polymerase chain reaction; DLI, donor lymphocyte infusion.

Of the 49 patients treated with DLI, 10 patients are still receiving escalating doses of lymphocytes, and 39 patients have completed this therapy and are evaluable for response. Overall, 23 of 39 patients have achieved a molecular remission after DLI. The probability of achieving a molecular remission at 2 years seemed higher (although not statistically significant) among patients with negative or low-level positive RT-PCR (83%; n = 12) compared to patients with high-level positive RT-PCR (60%; n = 27).

Survival and disease-free survival

The actuarial overall survival (OS) for the entire group was 67.4% (range, 61% to 73%) at 5 years. For patients with a high-level positivity, the OS was 56.7% (range, 40% to 72%) at 5 years compared with 92.9% (range, 68% to 99%) and 71% (range, 56% to 83%) for patients with low-level positive and negative RT-PCR, respectively (P = .02) (Figure3). The leukemia-free survival (LFS) for patients with high-level positive RT-PCR was 10.4% (range, 5% to 22%) at 5 years compared with 50% (range, 27% to 74%) and 50.7% (range, 34% to 67%) for patients with low-level positive and negative RT-PCR, respectively (P < .0001) (Figure4). There were no statistically significant differences in OS and LFS between patients with negative and low-positive RT-PCR results. There were no statistically significant differences in OS and LFS between patients who had an early RT-PCR test (n = 138) and those who did not (n = 100) (data not shown).

Fig. 3.

OS after SCT for CML according to the results of an early RT-PCR test.

The P value shown has been pooled over strata. The pairwise over strata P values are: negative versus low positive,P = .1; negative versus high positive,P = .04; and low positive versus high positive,P = .02.

Fig. 3.

OS after SCT for CML according to the results of an early RT-PCR test.

The P value shown has been pooled over strata. The pairwise over strata P values are: negative versus low positive,P = .1; negative versus high positive,P = .04; and low positive versus high positive,P = .02.

Close modal
Fig. 4.

LFS after SCT for CML according to the results of an early RT-PCR test.

The P value shown has been pooled over strata. The pairwise over strata P values are: negative versus low positive,P = .1; negative versus high positive,P < .0001; and low positive versus high positive,P = .001.

Fig. 4.

LFS after SCT for CML according to the results of an early RT-PCR test.

The P value shown has been pooled over strata. The pairwise over strata P values are: negative versus low positive,P = .1; negative versus high positive,P < .0001; and low positive versus high positive,P = .001.

Close modal

RT-PCR is by far the most sensitive method to detect residual disease in CML and can enable a single leukemia cell to be detected in a background of 105 to 106 normal cells. This is approximately 1000-fold greater than the sensitivity of routine cytogenetic analysis.1 Many investigators (including ourselves) have used nonquantitative RT-PCR techniques to detect MRD in patients who have undergone allogeneic SCT for CML. Using a nested primer technique, Roth et al7 analyzed 64 CML patients after allogeneic SCT and detected BCR-ABL transcripts at one time point in 37 patients. They concluded that nested RT-PCR could define subgroups of patients in apparent clinical remission, but with an increased risk of disease recurrence. Others,22 also using nested RT-PCR, found no association between RT-PCR positivity and subsequent relapse. In an early study5 we showed that RT-PCR positivity within 6 months after transplantation did not predict a worse outcome, whereas RT-PCR positivity later than 6 months after transplantation did. Radich et al6 presented a comprehensive multivariate analysis of 346 patients after allogeneic SCT. They identified RT-PCR positivity at 6-12 months after SCT as one independent variable influencing subsequent relapse. The significance of the presence of BCR-ABL transcripts in predicting disease recurrence was, however, lost in patients who tested positive more than 36 months after SCT. More recently, Serrano et al23 have used a combination of lineage-specific chimerism and detection of p190BCR-ABL transcripts to predict relapse.

All these studies employed a nonquantitative PCR technique, which could only give a positive or negative answer. A quantitative technique that allows one to follow the kinetics of low-level PCR positivity may, however, be more valuable in the clinical setting. For example, a proportion of CML patients are BCR-ABL+ for prolonged periods after allogeneic SCT, but they do not satisfy conventional criteria for relapse; for such patients one or more positive RT-PCR results would be difficult to interpret. Conversely, serial quantitative RT-PCR techniques can distinguish those RT-PCR+ patients who have low or falling BCR-ABLlevels from those whose levels are increasing.13 Patients destined not to relapse after SCT have persistently undetectable, low, or falling BCR-ABL levels on sequential analysis; after 6 to 12 months, BCR-ABL transcripts are usually undetectable and remain so indefinitely. In contrast, increasing or persistently high levels of BCR-ABL messenger RNA (mRNA) precede relapse, often several months before the cytogenetic detection of the Ph+ chromosome marrow metaphases.1 13 Provided assays are performed with sufficient frequency, rising or persistently high numbers of BCR-ABL transcripts can be detected prior to frank relapse, and this information may be used for early therapeutic intervention.

This study has focused on the potential association between a quantitative RT-PCR test performed early after SCT (at 3 to 5 months) and subsequent outcome. For the purposes of this investigation patients were classified into 3 groups (high-level positive, low-level positive, and negative) according to the level of quantitation (see “Patients, materials, and methods”). The cutoff between low-level and high-level transcript numbers was based on our previous experience. In our laboratory, patients who have a BCR-ABL/ABL ratio of less than 0.02% fall below the detection of relapse by cytogenetic analysis. Moreover, on sequential analysis, some patients with a ratio above 0.02% remained continuously RT-PCR+ in long-term follow-up, and some patients below such threshold were likely to fluctuate between positive and negative RT-PCR results.13This level correlates with a burden of CML which is approximately 50-fold lower than that seen in early cytogenetic relapse.1 13 Before 1996, quantitative results were expressed in numbers of BCR-ABL transcripts per μg RNA. Assuming a good quality sample, 100 transcripts per μg RNA corresponds to a BCR-ABL/ABL ratio of 0.02%.

We have found that 63 of the 138 patients had a high-level of RT-PCR positivity early after SCT. Early RT-PCR was able to differentiate between 3 well-defined groups, with different probabilities of developing disease recurrence. Those with high-level positivity had an extremely high risk of relapse; those with a negative RT-PCR result had a low probability, and those with a low-level RT-PCR positivity had an intermediate risk of disease recurrence 3 years after SCT. This correlation remained significant when only patients who had progressed to or beyond cytogenetic relapse were considered. Patients with negative RT-PCR results soon after SCT had more than a 95% probability of remaining free of leukemia at the chromosomal level 2 years after SCT.

The association between early RT-PCR and relapse was particularly strong in patients who underwent a TCD and URD SCT. This finding may represent a reduced graft-versus-leukemia effect in this type of transplantation.24 When rigorous TCD is performed, the antileukemic efficacy of the SCT must be due largely to the chemoradiotherapy of the conditioning. If this fails to eradicate the leukemia, as measured by a positive early RT-PCR, then relapse is the likely outcome. The kinetics of disappearance of residual disease may prove informative, as has been shown in acute lymphoblastic leukemia and acute promyelocytic leukemia.25-28 

The overall relapse rate in this study was relatively high. This may, in part, have reflected the use of Campath as an in vivo method of TCD. An additional factor could also have been prolonged use of post-SCT immunosuppression. Withdrawal of immunosuppression can result in an enhanced graft-versus-leukemia effect in some patients.29 30 Early RT-PCR could be a useful tool in deciding when to stop cyclosporine or other immunosuppressive agents and thus reduce the risk of relapse. In this series, more than 70% of patients with high-level positive RT-PCR relapsed within 9 months after SCT, and more than 48% of patients had relapsed at the cytogenetic level. Thus many patients were still on immunosuppressive therapy at the time of relapse.

DLI has become a standard treatment for patients who relapse after allogeneic SCT. Responses to DLI are higher in patients with molecular or cytogenetic relapse compared with hematologic relapse.31-34 Furthermore, DLI is much less effective in patients with advanced disease (accelerated or blastic phase).33 Patients in the low- and high-level positive groups were more likely to receive DLI in hematologic relapse compared with the negative RT-PCR group. At our center, the median interval between first recognition of relapse and institution of DLI is more than 9 months. Because this is partly due to the delay in diagnosing relapse, early RT-PCR could reduce this delay.

In summary, this study has shown the usefulness of a quantitative RT-PCR performed early after SCT. Patients who remain RT-PCR+ at a high level soon after SCT have an increased risk of relapse and are more likely to progress in the short-term, thereby limiting the efficacy of post-SCT therapies. These patients may represent a subgroup with biologically distinct characteristics and a different response to DLI. Conversely, patients with a negative RT-PCR have an excellent prognosis. An intermediate subgroup of patients was identified with an intermediate risk of relapse, although after relapse the disease was less aggressive. Patients in this intermediate group may resemble patients treated by “nonmyeloablative” SCT, and the kinetics of response to treatment with DLI may be similar in the 2 groups.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Cross
NCP
Minimal residual disease in CML.
Hematol Cell Ther.
40
1998
224
228
2
Lion
T
Henn
T
Gaiger
A
Kalhs
P
Gadner
H
Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia.
Lancet.
341
1993
275
279
3
Cross
NCP
Melo
JV
Lin
F
Goldman
JM
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.
Leukemia.
8
1994
186
190
4
Cross
NCP
Detection of BCR-ABL in hematological malignancies by RT-PCR.
Molecular Diagnosis of Cancer.
Cotter
FE
1996
25
29
Humana
Totowa, NJ
5
Hughes
TP
Morgan
GJ
Martiat
P
Goldman
JM
Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.
Blood.
77
1991
874
878
6
Radich
JP
Gehly
G
Gooley
T
et al
Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
Blood.
85
1995
2632
2638
7
Roth
MS
Antin
JH
Ash
R
et al
Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia.
Blood.
79
1992
276
282
8
Lee
M
Khouri
I
Champlin
R
et al
Detection of minimal residual disease by polymerase chain reaction of bcr/abl transcripts in chronic myelogenous leukaemia following allogeneic bone marrow transplantation.
Br J Haematol.
82
1992
708
714
9
Gaiger
A
Lion
T
Kalhs
P
et al
Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Leukemia.
7
1993
1766
1771
10
Faderl
S
Talpaz
M
Kantarjian
HM
Estrov
Z
Should polymerase chain reaction analysis to detect minimal residual disease in patients with chronic myelogenous leukemia be used in clinical decision making?
Blood.
93
1999
2755
2759
11
Cross
NCP
Feng
L
Chase
A
Bungey
J
Hughes
TP
Goldman
JM
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Blood.
82
1993
1929
1936
12
Lion
T
Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia.
Bone Marrow Transplant.
14
1994
505
509
13
Lin
F
van Rhee
F
Goldman
JM
Cross
NCP
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Blood.
87
1996
4473
4478
14
Mensink
E
van de Locht
A
Schattenberg
A
et al
Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukaemia patients using real-time quantitative RT-PCR.
Br J Haematol.
102
1998
768
771
15
Thompson
JD
Brodsky
I
Yunis
JJ
Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation.
Blood.
79
1992
1629
1635
16
Hochhaus
A
Lin
F
Reiter
A
et al
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-therapy by competitive polymerase chain reaction.
Blood.
87
1996
1549
1555
17
Hochhaus
A
Reiter
A
Saubele
S
et al
Molecular heterogeneity in complete cytogenetic responders after interferon-therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission.
Blood.
95
2000
62
66
18
Spencer
A
Szydlo
RM
Brookes
PA
et al
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
Blood.
86
1995
3590
3597
19
Savage
DG
Szydlo
RM
Chase
A
Apperley
JF
Goldman
JM
Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse.
Br J Haematol.
99
1997
30
35
20
Kaplan
E
Meier
P
Nonparametric estimation from incomplete observations.
J Am Stat Assoc.
53
1958
547
550
21
Gooley
T
Leisenrin
W
Crowley
J
Storer
BE
Estimation of failure probabilities in the presence of competing risks.
Stat Med.
18
1999
695
706
22
Miyamura
K
Tahara
T
Tanimoto
M
et al
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
Blood.
81
1993
1089
1093
23
Serrano
J
Roman
J
Sanchez
J
et al
Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210 BCR-ABL and p190 BCR-ABL after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190 BCR-ABL detection precede cytogenetic relapse.
Blood.
95
2000
2659
2665
24
Goldman
JM
Gale
RP
Horowitz
MM
et al
Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion.
Ann Intern Med.
108
1988
806
814
25
Cavé
H
van der Werff ten Bosch
J
Suciu
S
et al
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia.
N Engl J Med.
339
1998
591
596
26
Diverio
D
Rossi
V
Avvisati
G
et al
Early detection of relapse by prospective RT-PCR analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter “AIDA” trial.
Blood.
92
1998
784
789
27
Pongers-Willemse
MJ
Verhagen
OJ
Tibbe
GJ
et al
Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
Leukemia.
12
1998
2006
2014
28
Burnett
AK
Grimwade
D
Solomon
E
Wheatley
K
Goldstone
AH
Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.
Blood.
93
1999
4131
4143
29
Arcese
W
Goldman
JM
D'Arcangelo
E
et al
Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia: Chronic Leukemia Working Party. European Bone Marrow Transplantation Group.
Blood.
82
1993
3211
3219
30
Higano
CS
Chielens
D
Raskind
W
et al
Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.
Blood.
90
1997
2549
2554
31
Dazzi
F
Szydlo
RM
Goldman
JM
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
Exp Hematol.
27
1999
1477
1486
32
van Rhee
F
Lin
F
Cullis
JO
et al
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.
Blood.
83
1994
3377
3383
33
Kolb
HJ
Schattenberg
A
Goldman
JM
et al
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia.
Blood.
86
1995
2041
2050
34
Dazzi
F
Szydlo
RM
Craddock
C
et al
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.
Blood.
95
2000
67
71

Author notes

Eduardo Olavarria, Department of Haematology, Hammersmith Hospital, ICSM, Du Cane Rd, London W12 0NN, England; e-mail: e.olavarria@ic.ac.uk.

Sign in via your Institution